T 1.908.673.1030

Corporate Headquarters Hikma Pharmaceuticals USA Inc. 200 Connell Drive, 4th Floor Berkeley Heights, NJ 07922

## VIA ELECTRONIC MAIL

Office of the Vermont Attorney General 109 State Street Montpelier, Vermont 05609 AGO.highcostprescriptiondrugs@vermont.gov

June 1, 2021

Dear Sir/Madam,

In compliance with 18 V.S.A. § 4637, Hikma Pharmaceuticals USA Inc. ("Hikma") hereby provides the Office of Attorney General with notice that Hikma has introduced new generic prescription drugs (the "Products") at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program. A schedule identifying such Products is set forth as Exhibit A.

Additionally, in compliance with 18 V.S.A. § 4637(c) as further refined by 18 V.S.A. § 4637 (d), Hikma hereby provides the following information which is in the public domain or publicly available:

- (1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
  - a. These drugs are generic products; therefore, no marketing and pricing plans are available. These products are sold in the United States only.
- (2) The estimated volume of patients who may be prescribed the drug:
  - a. The estimated average number of patients per month is unknown to Hikma.
- (3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
  - a. Not applicable.
- (4) The date and price of acquisition if the drug was not developed by the manufacturer;
  - a. Hikma did not acquire these products.

Finally, Hikma would like to confirm that: (i) the Office of the Attorney General has not yet provided a format for submissions under this section; and (ii) this notice is an appropriate means of submitting the required information.

Very truly yours,

Heather Skye Patrick Sr. Analyst, Legal Affairs

Heather S. Patrick

Hikma Pharmaceuticals USA Inc

www.hikma.com



## **EXHIBIT A**

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
0054-0576-25	Deferiprone Tablets, 500mg, 1 bottle of 100	5/29/2021	\$6,148.08
0054-0426-23	Rufinamide Tablets, 400mg, 1 bottle of 120	5/30/2021	\$737.04